Bowden Christopher 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 11, 2021
Insider Transaction Report
Form 4
Bowden Christopher
Chief Medical Officer
Transactions
- Sale
Common stock
2021-06-09$60.16/sh−7,149$430,117→ 15,487 total - Exercise/Conversion
Common stock
2021-06-10$39.76/sh+20,853$829,115→ 36,340 total - Sale
Common stock
2021-06-10$60.06/sh−20,853$1,252,437→ 15,487 total - Exercise/Conversion
Stock option (right to buy)
2021-06-10−20,853→ 4,387 totalExercise: $39.76Exp: 2026-02-15→ Common stock (20,853 underlying) - Exercise/Conversion
Common stock
2021-06-09$39.76/sh+7,149$284,244→ 22,636 total - Exercise/Conversion
Stock option (right to buy)
2021-06-09−7,149→ 25,240 totalExercise: $39.76Exp: 2026-02-15→ Common stock (7,149 underlying)
Footnotes (5)
- [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.29. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.